MBK-01 for clostridium infections

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Oct 2021: Trial started, NCT05201079
  2. 21 Jan 2022: Trial registered, NCT05201079

The trials

NCT05201079: Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin

State
Completed
Phase
Phase 3
People
93 taking part
Started
29 Oct 2021
Primary completion
15 Nov 2023
Arms
MBK-01
Results
Posted on the registry
  1. 29 Oct 2021: Trial started
  2. 21 Jan 2022: Trial registered
  3. 15 Nov 2023: Trial completed
  4. 25 Mar 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.